Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Show more
103 Carnegie Center, Princeton, NJ, 08540, United States
Market Cap
37.92M
52 Wk Range
$1.79 - $5.18
Previous Close
$2.33
Open
$2.35
Volume
77,596
Day Range
$2.29 - $2.37
Enterprise Value
20.86M
Cash
16.98M
Avg Qtr Burn
-1.695M
Insider Ownership
25.73%
Institutional Own.
26.24%
Qtr Updated
03/31/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
GTx-104 Details Aneurysmal subarachnoid hemorrhage (aSAH) | NDA FDA meeting | |
GTx-101 (Local Anesthetic) Details Postherpetic Neuralgia | Phase 1 Update | |
GTx-102 Details Ataxia-Telangiectasia | Phase 1 Update |
